戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tion of allergic patients (e.g., in food and drug allergy).
2 tion should potentially not be allowed (e.g. drug allergy).
3 od allergies, anaphylaxis, insect venom, and drug allergy.
4 is and management of patients with suspected drug allergy.
5              None correlated with history of drug allergy.
6 ms, diagnosis, management, and prevention of drug allergy.
7  Infectious Diseases sponsored a workshop on drug allergy.
8 o issue an International CONsensus (ICON) on drug allergy.
9 e of 0.02-0.4 g), and 4 of 368 patients with drug allergy.
10  allograft dysfunction such as infection and drug allergy.
11 s, heart failure, chronic kidney disease, or drug allergy.
12 result and may be considered indicative of a drug allergy.
13 AT in the diagnosis of IgE-mediated food and drug allergies.
14 red questionnaire on environmental, food and drug allergies.
15 new concepts for treatment and prevention of drug allergies.
16 esponses, including food, environmental, and drug allergies.
17 included food allergy (4.2%, 6.4%: p = 1.0), drug allergy (37.5%, 16.6%: p = 0.02), allergic rhinitis
18                              In IgE-mediated drug allergies, a possible tolerance mechanism to the dr
19 8; 95% CI, 1.4-16.4) and parental history of drug allergy (adjusted odds ratio = 3.0; 95% CI, 1.3-6.8
20                   A drug allergy passport, a drug allergy alert card, a certificate, and a discharge
21 x types of allergic reactions: food allergy, drug allergy, allergic contact dermatitis, allergic rhin
22  support quality management of patients with drug allergies and better facilitate healthcare planning
23  to support the diagnosis of food, venom and drug allergies and chronic urticaria, to monitor the nat
24 e aimed to describe the prevalence of common drug allergies and patient characteristics documented in
25 al disease, metabolic bone disease, cancers, drug allergies and toxic effects, and complications asso
26 completing testing and surveys had 1 or more drug allergies and were recruited from allergy clinics a
27 n of patients with food-, insect venom-, and drug allergy and chronic urticaria.
28 actams are among the most frequent causes of drug allergy and constitute an important clinical proble
29                Thus, the European Network on Drug Allergy and Drug Allergy Interest Group of the Euro
30                      The European Network on Drug Allergy and Drug Allergy Interest Group of the Euro
31                Thus, the European Network on Drug Allergy and Drug Allergy Interest Group of the Euro
32 ts were excluded before randomization due to drug allergy and opted for alternative treatment (5.8%),
33          Members of the European Network for Drug Allergy and the European Academy of Allergy and Cli
34 ity (anaphylaxis, respiratory allergies, and drug allergies) and vaccines given.
35 atients with AOSD had a higher prevalence of drug allergy, and allergic rhinitis/allergic conjunctivi
36 tial for precision medicine in food allergy, drug allergy, and anaphylaxis under the auspices of the
37 od allergy, atopic dermatitis, some forms of drug allergy, and insect sting allergy).
38 is, asthma, atopic dermatitis, food allergy, drug allergy, and primary immune deficiency disease in r
39 nditions: asthma, anaphylaxis, food allergy, drug allergy, and urticaria.
40 physiology and diagnosis of non-IgE-mediated drug allergy are offered, with novel data regarding the
41 y be allergic or nonallergic in nature, with drug allergies being immunologically mediated DHRs.
42  the 1250 outpatients referred for suspected drug allergy between July 2013 and June 2014 were evalua
43 e potentially wide-reaching for IgE-mediated drug allergy but also allergy in general.
44 n medicine approach to treatment of food and drug allergy, but further validation and quantification
45     Standardized protocols, including DPT in drug allergy centers, are essential to differentiate pro
46 ealth and Care Excellence (NICE) Guidance on Drug Allergy-CG183.
47 nce of dedicated categories for food and non-drug allergies contributes to systematic underreporting.
48                                              Drug allergy (DA) remains a complex and unaddressed prob
49                                              Drug allergy data were obtained from EHRs of patients wh
50 neity exists in NHS EPR systems and food/non-drug allergy documentation practices.
51 gy passport as well as general guidelines of drug allergy documentation.
52                            The prevalence of drug allergies documented in electronic health records (
53                          European Network on Drug Allergy/EAACI protocol was appropriate and safe whe
54 hylaxis, angioedema, asthma, conjunctivitis, drug allergies, eczema, food allergy, rhinitis, urticari
55 igated according to the European Network for Drug Allergy (ENDA) guidelines and patients found to be
56                          European Network on Drug Allergy (ENDA) has proposed an algorithm for diagno
57 NSAIDs) proposed by the European Network for Drug Allergy (ENDA) interest group (2011) was revised in
58 nes were devised by the European Network for Drug Allergy (ENDA) on behalf of the European Academy of
59   While the reaction history is critical for drug allergy evaluations and is typically self-reported,
60 uidelines for investigation of perioperative drug allergy exist, but the quality of services is unkno
61 ng system developed through the consensus of drug allergy experts from the United States Drug Allergy
62                                       Unlike drug allergies, food and non-drug allergens lack standar
63      The clinical allergy section focuses on drug allergy, food allergy and immunotherapy.
64                        The environmental and drug allergy groups did not show significant differences
65 linical Immunology (EAACI) Interest Group on Drug Allergy has performed a literature search on skin t
66 is no validated survey instrument to collect drug allergy history from patients.
67                                          The drug allergy history tool (DAHT) was revised after 3 rou
68 arch to obtain standardized patient-reported drug allergy history.
69 ey instrument that collects patient-reported drug allergy history.
70                   The most commonly reported drug allergies in this population were to penicillins (1
71 (BLs) are the most frequent manifestation of drug allergy in children.
72 cs and consequently the most common cause of drug allergy in the world.
73                                              Drug "allergies" in general, but most those notably to p
74                                  Advances in drug allergy include identification of HLA associations
75 eliable and valid source of patient-reported drug allergy information.
76 rvey was emailed to all members of the EAACI Drug Allergy Interest Group (DAIG) between February and
77 y of Allergy and Clinical Immunology (EAACI) Drug Allergy Interest Group (DAIG) on how European aller
78 us, the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of A
79     The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of A
80 us, the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of A
81                             The diagnosis of drug allergy is complex and represents a serious challen
82                             The diagnosis of drug allergy is often based on history alone, which is a
83 ite, 11% Hispanic ethnicity), 29 with single drug allergy labels and 50 with multiple drug allergy la
84                              The most common drug allergy labels were penicillins (77%), sulfonamides
85 gle drug allergy labels and 50 with multiple drug allergy labels.
86 any evidence of immune activation in a mouse drug allergy model.
87 The plasma samples, in contrast, came from 3 drug allergy-negative control patients, or 2 cefazolin-a
88                Penicillin is the most common drug "allergy" noted at hospital admission, although it
89                                              Drug allergies occur when hapten-like drug metabolites c
90 rrect diagnosis of other conditions, such as drug allergy or autoimmune disease.
91 sthma, definitions of endotypes for food and drug allergy or for anaphylaxis lag behind.
92  exceptions were clinical contraindications, drug allergies, or drug intolerances.
93 rtion of each allergy to the total number of drug allergies over time.
94 llergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on
95 ogy have formed a task force and developed a drug allergy passport as well as general guidelines of d
96                                            A drug allergy passport should at least contain informatio
97                                            A drug allergy passport, a drug allergy alert card, a cert
98 eported drug allergy with an average of 1.95 drug allergies per patient.
99 in test reagents, lack of formal training in drug allergy, pre-emptive, non-standardised and unregula
100 ionnaire (Study-Q), the European Network for Drug Allergy Questionnaire (ENDA-Q), and confirmatory di
101  implicated in systemic hypersensitivity and drug allergy reactions, are targeted by a polyclonal pop
102  drug allergy experts from the United States Drug Allergy Registry (USDAR) Consortium.
103            Our understanding of IgE-mediated drug allergy relies on the hapten concept, which is well
104                        In addition, food and drug allergies represent a neglected area of research in
105 ta-lactam antibiotics as a valuable tool for drug allergy research and diagnostic tests.
106 proach for generating reference materials in drug allergy research and diagnostics.
107 rmacogenomics discussed the current state of drug allergy research.
108 ion influences the risk of commonly reported drug allergies such as penicillin allergy remains largel
109 icle based in vitro diagnostic technique for drug allergies to two common platinum-based chemotherape
110                     Many notable advances in drug allergy, urticaria, angioedema, and anaphylaxis wer
111  outcomes and paths forward in patients with drug allergy, urticaria, HAE, and anaphylaxis.
112 quency of patients having 1, 2, 3..., or 10+ drug allergies was reported.
113                                              Drug allergies were most prevalent among females and whi
114  35.5% of patients had at least one reported drug allergy with an average of 1.95 drug allergies per
115        International experts in the field of drug allergy with backgrounds in allergy, immunology, in
116 4 [1.3-8.9], and with cANCA 3.3 [1.0-10.8]), drug allergy (with PSV 3.6 [1.8-7.0], with WG 4.0 [1.8-8
117 ast to patients who had undergone a complete drug allergy workup.
118 ta-lactam (BL) allergies are the most common drug allergy worldwide, but most are reported in error.

 
Page Top